-DOCSTART- -X- O
The -X- _ O
identification -X- _ O
of -X- _ O
a -X- _ O
novel -X- _ B-Patient
β -X- _ I-Patient
coronavirus -X- _ I-Patient
, -X- _ I-Patient
nCoV -X- _ I-Patient
, -X- _ O
as -X- _ O
the -X- _ O
causative -X- _ O
agent -X- _ O
of -X- _ O
severe -X- _ O
respiratory -X- _ O
illness -X- _ O
in -X- _ O
humans -X- _ O
originating -X- _ O
in -X- _ O
Saudi -X- _ O
Arabia -X- _ O
, -X- _ O
Qatar -X- _ O
and -X- _ O
Jordan -X- _ O
has -X- _ O
raised -X- _ O
concerns -X- _ O
about -X- _ O
the -X- _ O
possibility -X- _ O
of -X- _ O
a -X- _ O
coronavirus -X- _ O
pandemic -X- _ O
similar -X- _ O
to -X- _ O
that -X- _ O
of -X- _ O
SARS-CoV. -X- _ O
As -X- _ O
a -X- _ O
definitive -X- _ O
treatment -X- _ O
regimen -X- _ O
has -X- _ O
never -X- _ O
been -X- _ O
thoroughly -X- _ O
evaluated -X- _ O
for -X- _ O
coronavirus -X- _ O
infections -X- _ O
, -X- _ O
there -X- _ O
is -X- _ O
an -X- _ O
urgent -X- _ O
need -X- _ O
to -X- _ O
rapidly -X- _ O
identify -X- _ O
potential -X- _ O
therapeutics -X- _ O
to -X- _ O
address -X- _ O
future -X- _ O
cases -X- _ O
of -X- _ O
nCoV. -X- _ B-Patient
To -X- _ O
determine -X- _ O
an -X- _ O
intervention -X- _ O
strategy -X- _ O
, -X- _ O
the -X- _ O
effect -X- _ O
of -X- _ O
interferon-α2b -X- _ B-Intervention
and -X- _ I-Intervention
ribavirin -X- _ I-Intervention
on -X- _ O
nCoV -X- _ B-Patient
isolate -X- _ O
hCoV-EMC -X- _ B-Patient
/ -X- _ I-Patient
2012 -X- _ I-Patient
replication -X- _ O
in -X- _ O
Vero -X- _ O
and -X- _ O
LLC-MK2 -X- _ O
cells -X- _ O
was -X- _ O
evaluated. -X- _ O
hCoV-EMC -X- _ B-Outcome
/ -X- _ I-Outcome
2012 -X- _ I-Outcome
was -X- _ I-Outcome
sensitive -X- _ I-Outcome
to -X- _ I-Outcome
both -X- _ I-Outcome
interferon-α2b -X- _ I-Outcome
and -X- _ I-Outcome
ribavirin -X- _ I-Outcome
alone -X- _ I-Outcome
in -X- _ I-Outcome
Vero -X- _ I-Outcome
and -X- _ I-Outcome
LLC-MK2 -X- _ I-Outcome
cells -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
only -X- _ I-Outcome
at -X- _ I-Outcome
relatively -X- _ I-Outcome
high -X- _ I-Outcome
concentrations -X- _ I-Outcome
; -X- _ I-Outcome
however -X- _ I-Outcome
, -X- _ I-Outcome
when -X- _ I-Outcome
combined -X- _ I-Outcome
, -X- _ I-Outcome
lower -X- _ I-Outcome
concentrations -X- _ I-Outcome
of -X- _ I-Outcome
interferon-α2b -X- _ I-Outcome
and -X- _ I-Outcome
ribavirin -X- _ I-Outcome
achieved -X- _ I-Outcome
comparable -X- _ I-Outcome
endpoints. -X- _ I-Outcome
Thus -X- _ I-Outcome
, -X- _ I-Outcome
a -X- _ I-Outcome
combination -X- _ I-Outcome
of -X- _ I-Outcome
interferon-α2b -X- _ I-Outcome
and -X- _ I-Outcome
ribavirin -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
are -X- _ I-Outcome
already -X- _ I-Outcome
commonly -X- _ I-Outcome
used -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
clinic -X- _ I-Outcome
, -X- _ I-Outcome
may -X- _ I-Outcome
be -X- _ I-Outcome
useful -X- _ I-Outcome
for -X- _ I-Outcome
patient -X- _ I-Outcome
management -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
event -X- _ I-Outcome
of -X- _ I-Outcome
future -X- _ I-Outcome
nCoV -X- _ I-Outcome
infections -X- _ I-Outcome
. -X- _ O

